Abstract
Oxaprozin is an oxazole-propionic acid derivate with potency to inhibite three distinct enzymatic systems: COX enzymes, anandamide hydrolase and the NF-kappa B activating pathway. Oxaprozin inhibits both COX isoforms, anandamide catabolism, and translocation of NF-kappa B into the nucleus where it acts as a transcription factor.
The major pharmacodynamic properties represent the basis of anti-inflammatory and analgetic (but also anti-pyrogenic) potency of the drug. The clinical efficacy of oxaprozin has been demonstrated in a large group of rheumatic disease, especially in rheumatoid arthritis, osteoarthritis, periarthritis of the shoulder, and in various soft tissue inflammatory disorders.
Meta-analyses versus alternative in the treatment of rheumatic disese incl. some cases resistent to other NSAID, for example in periarthritis of the shoulder.